MacroGenics Collects $1.7B From Gilead for Bispecific Cancer Antibody MGD024

Gilead Sciences is continuing to follow through with its recent lean into the oncology space. The research-based biopharmaceutical company is set to pay a $60 million upfront fee to license a bispecific antibody from monoclonal antibody developer MacroGenics (MG)...